Check for updates





Blood 142 (2023) 71-74

The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

627.AGGRESSIVE LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration Fabian Frontzek^{1,2}, Loïc Renaud, MD³, Ulrich Duehrsen, MD⁴, Viola Poeschel, MD⁵, Sophie Bernard⁶, Loïc Chartier⁷, Nicolas Ketterer, MD⁸, Christian Recher, MD PhD⁹, Olivier Fitoussi¹⁰, Gerhard Held, MD¹¹, Rene-Olivier Casasnovas, MD¹², Corinne Haioun, MD PhD¹³, Nicolas Mounier¹⁴, Hervé Tilly, MD PhD¹⁵, Franck Morschhauser, MDPhD¹⁶, Steven Le Gouill, MD PhD¹⁷, Imke E. Karsten², Gerben Duns, PhD¹⁸, Christian Steidl, MD PhD¹⁹, David W. Scott, PhDMD, FRACP, FRCPA²⁰, Wolfram Klapper²¹, Andreas Rosenwald, MD²², German Ott, MD²³, Thierry Jo Molina, MDPhD²⁴, Georg Lenz²⁵, Marita Ziepert, PhD²⁶, Bettina Altmann, PhD²⁶, Catherine Thieblemont, MD PhD²⁷, Norbert Schmitz, MD²⁸ ¹BC Cancer Research Centre, Vancouver, Canada ²Department of Medicine A, University Hospital Muenster, Muenster, Germany ³Gustave Roussy, Paris, France ⁴Universitaetsklinikum Essen, Klinik Fuer Haematologie, Essen, DEU ⁵Saarland University Medical School, Homburg/Saar, Germany ⁶ Service Hématologie, Centre hospitaliser de la côte basque, Bayonne, France ⁷ LYSARC, Pierre Bénite, France ⁸Clinique Bois-Cerf, Lausanne, CHE ⁹ Service d'Hématologie, Centre Hospitalo-universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, UPS, INSERM, CNRS, Toulouse, France, Toulouse, France ¹⁰Oncologie-Hematologie, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FRA ¹¹Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany ¹²CHU DE DIJON - HÔPITAL F. MITTERRAND, Dijon, FRA ¹³ Lymphoid Malignancies Department, Henri Mondor University Hospital, AP-HP, Créteil, France ¹⁴CHU De Nice, Hôpital De L Archet, Nice, France ¹⁵Centre Henri-Becquerel and University of Rouen, Rouen, France ¹⁶Hematology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France ¹⁷Hematology Department, Institut Curie, Paris, France ¹⁸BC Cancer, Vancouver, Canada ¹⁹Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada ²⁰Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada ²¹Department of Pathology, University Hospital Schleswig-Holstein, Kiel, DEU ²²Institute of Pathology, Julius-Maximilians-Universität Würzburg, Wuerzburg, Germany ²³ Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany ²⁴Necker enfants malades, APHP, Paris, Paris, FRA ²⁵University of Münster, Munster, Germany ²⁶ Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany ²⁷ Service d'hémato-oncologie, Hôpital Saint-Louis, Paris, France ²⁸University Hospital Münster, Münster, DEU

Introduction: Depending on clinical and molecular risk factors, CNS relapse occurs in 1-15% of DLBCL patients (pts) and is associated with dismal outcomes. Despite its important role in further improving DLBCL therapy, a comprehensive and large-scale characterization of secondary CNS relapse remains challenging.

ORAL ABSTRACTS

Methods: We conducted retrospective analysis of 7775 pts treated within 19 prospective German and French phase 2/3 trials to identify and characterize DLBCL pts with progression or relapse in the CNS. Pts with histology different from DLBCL (subtypes), not treated with anti-CD20 antibody, or displaying CNS involvement at diagnosis were excluded from the analysis. **Results:** Among 5289 eligible pts, 159 (3%) experienced progression or relapse in the CNS. Median age at diagnosis was 62 years (range: 19-80 years), 47% of pts were female. In 91% of all cases, reference pathology confirmed the diagnosis of DLBCL. At diagnosis, 28 pts (18%), 62 pts (39%), and 69 pts (43%) had a low (0-1 point), intermediate, and high CNS IPI (4-6 points), respectively. 133 pts received front-line therapy with R/O-CHOP, 19 pts with R-(Mega)CHOEP, and 7 pts with R/O-ACVBP. Following first-line therapy, 54% of pts achieved a CR/CRu. For 131 pts (82%), CNS progress/ relapse represented the first PFS event. Prior to the CNS event, salvage therapy was administered to 30 pts, including 11 pts treated with HDT/ASCT and one pt receiving allogeneic SCT.

For 70 out of 158 pts (44%), CNS involvement was classified as intracerebral, 31% showed meningeal, and 3% intraspinal lymphoma involvement. In 22% of pts, CNS involvement was classified as combined including 5 cases with eye involvement. The CNS event occurred as progression without prior CR/ CRu of disease in 61 out of 159 pts (38%). For 155 pts it could be specified that 25% had an isolated progress in the CNS while 12% showed both CNS and concomitant systemic progress. 35% of pts showed an isolated CNS relapse while 28% suffered from a combined relapse.

82% of all CNS events occurred within the first two years after randomization while 29 pts (18%) experienced a late CNS event after 24 months. Notably, 46% of pts with low CNS IPI developed a late CNS event compared to 9% with high CNS IPI at diagnosis (Fisher exact, p<0.001). During the course of disease, 138 pts (87%) showed extranodal lymphoma involvement outside the CNS. The most frequently involved extranodal sites were bone (34%), gastro-intestinal tract (21%), soft-tissue (21%), kidney/ adrenal gland (20%), lung (19%), and liver (18%).

In general, pts with CNS event had poor outcomes with a median OS of 3.4 months (95% CI 2.9-4.2) and a 2-year OS of only 15% (10-22%). While sex and initial (CNS) IPI had no impact on OS, we observed significantly worse OS for pts older than 70 years at diagnosis (log rank, p<0.001). OS was poor regardless of the site of CNS manifestation. Pts with isolated CNS disease demonstrated significantly better OS than pts with concomitant systemic involvement (p=0.023). Pts with CNS events occurring later than 24 months from randomization did not show improved OS compared to pts with early relapse/ progression (p=0.19).

Treatment categories were reported for 150 pts. 95 pts received immunochemotherapy (IC), 30 pts in combination with radiotherapy (RT). More precisely, 69 pts received salvage therapies containing systemic MTX and 22 pts underwent consolidation with HDT/ASCT (73% of which had thiotepa-based conditioning regimens). Three pts received allogeneic SCT for consolidation. 28 pts were treated with RT alone (+/- intrathecal therapy (IT)). 27 pts received only IT, corticosteroids, or no treatment. Pts consolidated with HDT/ ASCT or allogeneic SCT had superior outcomes with a 3-year OS of 36% (20%-66%) compared to 18% (7.5%-44%) for pts receiving IC and RT, and to 9.7% (3.9%-24%) and 9.5% (2.8-32%) for pts treated with IC or RT alone, respectively (**Fig. 1**). Overall, pts achieving a CR after CNS event (38/159, 24%) showed a 3-year OS of 52% (37-73%).


Conclusions: This large study including more than 5000 DLBCL pts all treated on prospective clinical trials highlights the unmet medical need to improve the outcome of DLBCL pts suffering from CNS relapse. About one third of pts who underwent transplantation showed long-term survival in contrast to all other pts displaying very dismal outcomes. Novel strategies including targeted therapies and CAR T cells will have to challenge the survival rates reported here.

Disclosures Renaud: Janssen: Honoraria; Takeda: Honoraria. Poeschel: Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, congress support; BeiGene: Membership on an entity's Board of Directors or advisory committees; Swedish Orphan Biovitrum GmbH: Membership on an entity's Board of Directors or advisory committees; PentixaPharm GmbH: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: travel expenses, congress support; Abbvie: Other: travel expenses, congress support; Genmab: Consultancy; Roche: Other: travel expenses, congress support; Janssen-Cilag: Consultancy; EUSA Pharma: Consultancy; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, congress support; AstraZeneca: Honoraria; Lilly: Membership on an entity's Board of Directors or advisory committees. Recher: Jazz Pharamceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Iqvia: Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees. Held: Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; MSD: Consultancy, Honoraria. Casasnovas: Abbvie: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria; BEIGENE: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GILEAD/KITE: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ROCHE: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; TAKEDA: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Tilly: ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board

ORAL ABSTRACTS

Session 627

of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Morschhauser: F. Hoffmann-La Roche Ltd, AbbVie, BMS, Genmab, Gilead, Novartis: Consultancy; F. Hoffmann-La Roche Ltd, Gilead, AbbVie: Membership on an entity's Board of Directors or advisory committees. Steidl: Seattle Genetics, AbbVie, and Bayer: Consultancy; Bristol Myers Squibb, Epizyme and Trillium Therapeutics Inc.: Research Funding. Scott: Abbvie, AstraZeneca, Incyte: Consultancy; Janssen and Roche: Research Funding. Molina: Janssen: Other: Travel and congress fees. Lenz: Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Lilly: Consultancy; Constellation: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Miltenyi: Consultancy, Membership on an entity's Board of Directors or advisory committees; PentixPharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Immagene: Consultancy; Genase: Consultancy; Hexal/Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; University Hospital Munster: Current Employment; NanoString: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BeiGene: Membership on an entity's Board of Directors or advisory committees. Thieblemont: Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding; Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Honoraria; Paris University, Assistance Publique, hopitaux de Paris (APHP): Current Employment; Kyte, Gilead, Novartis, BMS, Abbvie, F. Hoffmann-La Roche Ltd, Amgen: Honoraria; Cellectis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; Hospira: Research Funding; Gilead Sciences: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses; Janssen: Honoraria, Other: Travel Expenses. Schmitz: Astra Zeneca: Research Funding; Jansen: Research Funding; Roche: Research Funding; Allogene: Honoraria, Other: Travel Support; Miltenvi: Other: Travel Support; BMS: Current holder of stock options in a privately-held company.





https://doi.org/10.1182/blood-2023-178815